Patents by Inventor Erika Morizzo
Erika Morizzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897944Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: GrantFiled: January 17, 2018Date of Patent: February 13, 2024Assignee: Ablynx N.V.Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, An Cerdobbel
-
Publication number: 20230060574Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: ApplicationFiled: June 29, 2022Publication date: March 2, 2023Applicant: Ablynx N.V.Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, An Cerdobbel
-
Publication number: 20230050615Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: ApplicationFiled: June 29, 2022Publication date: February 16, 2023Applicant: Ablynx N.V.Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, Raf Ponsaerts, Ingrid Ottevaere, An Cerdobbel
-
Patent number: 11414480Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: GrantFiled: December 7, 2017Date of Patent: August 16, 2022Assignee: Ablynx N.V.Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, Raf Ponsaerts, Ingrid Ottevaere, An Cerdobbel
-
Patent number: 11414481Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: GrantFiled: January 17, 2018Date of Patent: August 16, 2022Assignee: Ablynx N.V.Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, An Cerdobbel
-
Patent number: 11312788Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: GrantFiled: July 17, 2018Date of Patent: April 26, 2022Assignee: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Publication number: 20200190217Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: ApplicationFiled: July 17, 2018Publication date: June 18, 2020Applicant: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Publication number: 20190367598Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: ApplicationFiled: January 17, 2018Publication date: December 5, 2019Applicant: Ablynx N.V.Inventors: Stephanie STAELENS, Soren STEFFENSEN, Erika MORIZZO, An CERDOBBEL
-
Publication number: 20190367596Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: ApplicationFiled: December 7, 2017Publication date: December 5, 2019Applicant: Ablynx N.V.Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, Raf Ponsaerts, Ingrid Ottevaere, An Cerdobbel
-
Publication number: 20190367597Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.Type: ApplicationFiled: January 17, 2018Publication date: December 5, 2019Applicant: Ablynx N.V.Inventors: Stephanie STAELENS, Soren STEFFENSEN, Erika MORIZZO, An CERDOBBEL
-
Publication number: 20190055322Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: ApplicationFiled: July 17, 2018Publication date: February 21, 2019Applicant: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Patent number: 10072098Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: GrantFiled: March 4, 2013Date of Patent: September 11, 2018Assignee: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Publication number: 20150044215Abstract: Polypeptides are provided that are capable of significantly inhibiting andor neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: ApplicationFiled: March 4, 2013Publication date: February 12, 2015Applicant: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Publication number: 20130109842Abstract: The present invention relates to amino acid sequences that are directed against the p19 subunit of IL-23; as well as protein, constructs and compounds comprising the same; and also nucleic acids encoding the same.Type: ApplicationFiled: April 28, 2011Publication date: May 2, 2013Applicant: Ablynx N.V.Inventors: Veronique De Brabandere, Marc Jozef Lauwereys, Erika Morizzo, Heidi Rommelaere, Ann Union, Gert Verheyden
-
Publication number: 20120264917Abstract: Biparatopic protein constructs that are directed against IL-23, and in particular against the p19 subunit of IL-23. The constructs comprise at least a first binding domain or binding unit directed against a first defined epitope on p19 and at least a second binding domain or binding unit directed against a second defined epitope on p19 (or the p19/p40 interface). The binding domains or binding units may in particular be a domain antibody, a single domain antibody, a dAb or a Nanobody®. The constructs and pharmaceutical compositions comprising the same can be used for the prevention and/or treatment of diseases and disorders associated with IL-23 or IL-23 mediated signaling, such as inflammation and inflammatory disorders such as colitis, Crohn's disease and IBD, infectious diseases, psoriasis, cancer, autoimmune diseases, sarcoidosis, transplant rejection, cystic Fibrosis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, viral infection, and common variable immunodeficiency.Type: ApplicationFiled: May 27, 2010Publication date: October 18, 2012Applicant: Ablynx N.V.Inventors: Michael John Scott Saunders, Christophe Blanchetot, Carlo Boutton, Heidi Rommelaere, Johannes Joseph Wilhelmus De Haard, Veronique De Brabandere, Marc Jozef Lauwereys, Erika Morizzo, Ann Union, Gert Verheyden